Chattanooga ’s Program in Women’s Oncology (CPIWO) is a member of the Gynecologic Oncology Group (GOG). This is a national cooperative group sponsored through the National Cancer Institute (NCI), dedicated to improving care in women with cancer. Selected trials will now be available. We also participate in trials sponsored through pharmaceutical companies. We believe this gives the women in the South Eastern Tennessee Region the opportunity to participate in research that may be the next best treatment for their disease; it also gives women a chance to help other women with the same condition.
GOG Mission Statement: " The Gynecologic Oncology Group (GOG) is a non-profit organization (national) with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group (gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, nurses, statisticians, basic scientists, quality of life experts, data managers and administrative personnel is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care." For more info, visit the GOG website at: www.gog.org .
Please feel free to call and ask questions about our research program: 423-266-3636.
What is Clinical
Research?
Clinical research,
which involves clinical trials and
other research protocols, are strictly
controlled human studies of new and emerging
therapies. This type of research involves real
people participating in studies that are done to
test whether a new drug, a new prevention strategy,
or a new screening test is safe and effective in
people.Clinical research allows doctors from various disciplines to
evaluate new forms of treatment, how best to apply
recent developments in medicine, and to ensure that
patients have the opportunity to receive the latest
state-of-the-art care
.--------------------------------------------------------------------------
CPIWO is offering these
clinical trials:
(Check
back for updates often.)
(CLICK ON A LINK TO GET DETAILED INFORMATION ON EACH TRIAL.)
New Post:
Protocol AMG 386
A Phase III, randomized, double blind trial of weekly Paclitaxel plus AMG 386 or Placebo in women with Recurrent Partially Platinum Sensitive or Resistent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
The NCT # for this study is NCT01204749 link:
http://clinicaltrials.gov/ct2/show/study/NCT01204749?term=nct01204749&rank=1
Ongoing Studies:
Protocol MORAb-003-004
A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse.
The NCT # for this study is NCT00849667 link:
http://clinicaltrials.gov/ct2/show/study/NCT00849667?term=nct00849667&rank=1
Protocol - EC-FV-06
A Randomized Double-Blind Phase III Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer
The NCT # for this study is NCT01170650 link:
http://clinicaltrials.gov/ct2/show/NCT01170650?term=ec-fv-06&rank=1
Protocol I1Y-MC-JFBF-
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The NCT # for this study is NCT01059643 link:
http://clinicaltrials.gov/ct2/show/NCT01059643?term=i1y-mc-jfbf&rank=1
Protocol GOG-0212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
The NCT # for this study is NCT00108745 Link:
http://www.clinicaltrials.gov/ct2/show/NCT00108745?spons_ex=Y&id=NCT00108745&rank=1
Protocol GOG-0249
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
The NCT # for the study is NCT00262821 link:
http://clinicaltrials.gov/ct2/show/NCT00807768?term=GOG+0249+NCT00807768&rank=1
CA163-196
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
The NCT # for the study is NCT00883116 link:
http://clinicaltrials.gov/ct2/show/NCT00883116?term=NCT00883116&rank=1
AGO-OVAR-12 / 1199.15
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer.
The NCT # for the study is NCT01015118 link:
http://clinicaltrials.gov/ct2/show/NCT01015118?term=NCT01015118&rank=1
